M.D., MBA, Chairman Department of Surgery, Renown Health
Christos Galanopoulos is Renown Health Vice President, Chairman of Surgery for Renown Health, past Co-Director of The Institute for Health Innovation and Chief Clinical Officer for the Renown Institute for Cancer, an Oncologic Surgeon, and founder of the startup software platform “myHalo.” As Co-Director of the Renown Institute for Health Innovation, he helped lead a team of physicians and scientists in developing the first of it’s kind research database of phenotypic, genomic, socioeconomic, and environmental data focused on population health. The IHI helps researchers explore the only database available globally that links clinical, genomic and environmental data into one comprehensive research platform. He has held many high-level leadership positions within hospital and governmental agencies, acted as a consultant for private industry, and a principle investigator in multiple clinical trials. As a Health Economist trained at the London School of Economics, Christos has a deep understanding of global healthcare needs and challenges, Health-Tech Assessment , behavioral and pharmaceutical economics, insurance markets, and macro/micro-economic impact of healthcare policy on population health. To complement the above skillset, he completed his MBA at the University of Michigan’s Ross School of Business. In 2012, he was awarded the Leadership Program in Health Policy and Management scholarship from the ACS at Brandeis Heller School for Social Policy and Management, and worked as a Health Policy Scholar for the American College of Surgeons. As a Vice President for Renown Health and Chief Clinical Officer of Cancer Services, Christos was responsible for a service line generating 20% of the $1.4 Billion in revenues (2017) for the health system. As part of the senior management team, he is responsible for development and execution of the strategic business plan, application of innovation, patient experience, health quality, population health, and the management of the health systems 6500+ employees.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: A growing number of hospitals are offering predictive medicine by screening entire populations or specific subgroups for genetic information in order to target interventions for common disorders such as heart disease, diabetes, and cancer. Such screening can help identify groups at risk so that primary- or secondary-prevention efforts can be initiated.